Skip to main content

Ortho Micronor Side Effects

Generic name: norethindrone

Medically reviewed by Last updated on Mar 22, 2024.

Note: This document contains side effect information about norethindrone. Some dosage forms listed on this page may not apply to the brand name Ortho Micronor.

Applies to norethindrone: oral tablet.

Serious side effects of Ortho Micronor

Along with its needed effects, norethindrone (the active ingredient contained in Ortho Micronor) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking norethindrone:

More common

Incidence not known

Other side effects of Ortho Micronor

Some side effects of norethindrone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Incidence not known

For Healthcare Professionals

Applies to norethindrone: compounding powder, oral tablet.


The most commonly reported side effects included cycle irregularity, spotting/breakthrough bleeding, and temporary amenorrhea.[Ref]


Common (1% to 10%): Uterine/vaginal bleeding and spotting/breakthrough bleeding, short-lasting amenorrhea

Uncommon (0.1% to 1%): Breast discomfort

Frequency not reported: Irregular/increased/decreased bleeding/delayed menstruation, change in menstrual flow, menorrhagia, vaginal hemorrhage, cervical secretion alteration, cervical erosions, prolonged anovulation, suppressed lactation, galactorrhea, mastodynia, breast tenderness/enlargement, genital discharge, withdrawal bleeding (on treatment discontinuation), premenstrual-type depression, changes in cervical squamocolumnar junction and secretions[Ref]

Nervous system

Common (1% to 10%): Dizziness, headache

Frequency not reported: Drowsiness, somnolence, concentration loss, migraine, tremor, cerebral thrombosis and embolism[Ref]


Common (1% to 10%): Injection site reaction, local skin reaction[Ref]


Common (1% to 10%): Nausea

Uncommon (0.1% to 1%): Bloating

Frequency not reported: Vomiting, abdominal pain, gastrointestinal disturbance[Ref]


Common (1% to 10%): Skin disorder

Frequency not reported: Angioedema, acne, hirsutism, alopecia, rash, pruritus, pruritic rash, melasma, chloasma, urticaria, exacerbation of existing skin conditions, sweating, allergic rash with and without pruritus[Ref]


Common (1% to 10%): Increased weight

Frequency not reported: Increased fasting insulin levels, Cushing's syndrome, decreased glucose tolerance, exacerbation of diabetes mellitus, glycosuria, weight gain/change, change in appetite, fluid retention, increased serum calcium and potassium levels, altered serum lipid and lipoprotein levels (e.g., decreased HDL, increased LDL/HDL ratio)[Ref]


Common (1% to 10%): Hypersensitivity reaction

Frequency not reported: Anaphylaxis/anaphylactoid reactions[Ref]


Uncommon (0.1% to 1%): Depressed mood/depression/clinical depression/metal depression

Frequency not reported: Insomnia, nervousness, libido change, mood swings[Ref]


Frequency not reported: Urge to cough, paroxysmal cough, respiratory distress, dyspnea, pulmonary embolism, voice deepening[Ref]


Frequency not reported: Retinal thrombosis, diabetic cataract, vision disorders, visual disturbance, contact lens intolerance, optic neuritis (may lead to partial or complete vision loss)[Ref]


Frequency not reported: Circulatory irregularity, thromboembolic disorders, thrombophlebitis, increased blood pressure/hypertension, edema[Ref]


Frequency not reported: Cholestatic liver changes/cholestatic jaundice, hepatitis, disturbed liver function, transient liver test abnormalities (e.g., AST, ALT, bilirubin)[Ref]


Frequency not reported: Fever, hyperpyrexia, fatigue, extremity pain[Ref]


Frequency not reported: Increased white cell and platelet counts[Ref]


Frequency not reported: Masculinization of the female fetus[Ref]


1. (2001) "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical

2. (2001) "Product Information. Nor-QD (norethindrone)." Watson Laboratories Inc

3. (2001) "Product Information. Aygestin (norethindrone)." Lederle Laboratories

4. Cerner Multum, Inc. "UK Summary of Product Characteristics."

5. Cerner Multum, Inc. "Australian Product Information."

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.